Pricing

GT Biopharma (GTBP)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Michael Breen
Employees:
8
8000 MARINA BLVD, SUITE 100, BRISBANE, CA, 94005
(800) 304-9888
    Formally known as:
  • GT BIOPHARMA INC
Stock Split History
DateRatio
2021-02-11 1:17
2024-02-05 1:30
GT Biopharma, Inc. focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate, is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company was formerly known as OXIS International, Inc
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available